Variation in Treatment Priorities for Chronic Hepatitis C: A Latent Class Analysis

Patient

Volumn 9, Issue 3, 2016, Pages 241-249

  Fraenkel, Liana ^a   Lim, Joseph ^a   Garcia Tsao, Guadalupe ^a   Reyna, Valerie ^b   Monto, Alexander ^c   Bridges, John F P ^d  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Cornell University ^*  (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON; RIBAVIRIN; ANTIVIRUS AGENT;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CHRONIC HEPATITIS C; COPING BEHAVIOR; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PATIENT PREFERENCE; PRIORITY JOURNAL; RESPONSIBILITY; VIRUS RESISTANCE; ADAPTIVE BEHAVIOR; AGED; ANTIVIRAL RESISTANCE; DECISION MAKING; HEPATITIS C, CHRONIC; PATIENT PARTICIPATION; PSYCHOLOGY;

ADAPTATION, PSYCHOLOGICAL; AGED; ANTIVIRAL AGENTS; DECISION MAKING; DRUG RESISTANCE, VIRAL; FEMALE; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; PATIENT PARTICIPATION; PATIENT PREFERENCE;

EID: 84945589558     PISSN: 11781653     EISSN: 11781661     Source Type: Journal    
DOI: 10.1007/s40271-015-0147-7     Document Type: Article

References (34)

1. Bridges JFP. Stated preference methods in health care evaluation: an emerging methodological paradigm in health economics. Appl Health Econ Health Policy. 2003;2:213–24.
2. Bridges JFP, Onukwugha E, Johnson FR, Hauber AB. Patient preference methods: a patient-centered evaluation paradigm. ISPOR Connect. 2007;13:4–7.
3. Flynn TN, Louviere JJ, Peters TJ, Coast J. Best–worst scaling: what it can do for health care research and how to do it. J Health Econ. 2007;26:171–89.
4. Ryan M, Farrar S. Using conjoint analysis to elicit preferences for health care. BMJ. 2000;320:1530–3.
5. Constantinescu F, Goucher S, Weinstein A, Fraenkel L. Racial disparities in treatment preferences for rheumatoid arthritis. Med Care. 2009;47:350–5.
6. Fraenkel L, Cunningham M, Peters E. Subjective numeracy and preference to stay with the status quo. Med Decis Mak. 2015;35:6–11.
7. Rosen HR. Chronic hepatitis C infection. N Engl J Med. 2011;364:2429–38.
8. Shiratori Y, Imazeki F, Moriyama M, Yano M, Arakawa Y, Yokosuka O, et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med. 2000;132:517–24.
9. Shindo M, Hamada K, Oda Y, Okuno T. Long-term follow-up study of sustained biochemical responders with interferon therapy. Hepatology. 2001;33:1299–302.
10. Kasahara A, Hayashi N, Mochizuki K, Takayanagi M, Yoshioka K, Kakumu S, et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Hepatology. 1998;27:1394–402.
11. Yoshida H, Arakawa Y, Sata M, Nishiguchi S, Yano M, Fujiyama S, et al. Interferon therapy prolonged life expectancy among chronic hepatitis C patients. Gastroenterology. 2002;123:483–91.
12. Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology. 2010;138:513–21.
13. Finn A, Louviere JJ. Determining the appropriate response to evidence of public concern: the case of food safety. J Public Policy Mark. 1992;11:12–25.
14. Flynn TN, Marley AAJ. Best-worst scaling: theory and methods. In: Hess S, Daly A, editors. Handbook of choice modeling. Cheltenham: Edward Elgar Publishing Limited; 2014. p. 178–201.
15. Bridges JF, Joy S, Gallego G, Blauvelt BM, Geschwind JF, Pawlik T. Priorities for hepatocellular carcinoma (HCC) control: a comparison of policy needs in five European countries. J Comp Policy Anal Res Pract. 2012;14:352–68.
16. Ross M, Bridges JF, Ng X, Wagner LD, Frosch E, Reeves G, et al. A best-worst scaling experiment to prioritize caregiver concerns about ADHD medication for children. Psychiatr Serv. 2015;66:208–11.
17. Imaeda A, Bender D, Fraenkel L. What is most important to patients when deciding about colorectal screening? J Gen Intern Med. 2010;25:688–93.
18. Najafzadeh M, Lynd LD, Davis JC, Bryan S, Anis A, Marra M, et al. Barriers to integrating personalized medicine into clinical practice: a best-worst scaling choice experiment. Genet Med. 2012;14:520–6.
19. Ratcliffe J, Flynn T, Terlich F, Stevens K, Brazier J, Sawyer M. Developing adolescent-specific health state values for economic evaluation: an application of profile case best-worst scaling to the Child Health Utility 9D. Pharmacoeconomics. 2012;30:713–27.
20. Youden WJ. Use of incomplete block replications in estimating tobacco-mosaic virus. Contributions. Boyce Thompson Institute for Plant. Research. 1937;8:41–8.
21. Youden WJ. Experimental designs to increase accuracy of greenhouse studies. Contributions. Boyce Thompson Institute for Plant Research. 1940;11:219–28.
22. Deal K. Segmenting patients and physicians using preferences from discrete choice experiments. Patient. 2014;7:5–21.
23. Brown DS, Poulos C, Johnson FR, Chamiec-Case L, Messonnier ML. Adolescent girls’ preferences for HPV vaccines: a discrete choice experiment. Adv Health Econ Health Serv Res. 2014;24:93–121.
24. Carroll FE, Al-Janabi H, Flynn T, Montgomery AA. Women and their partners’ preferences for Down’s syndrome screening tests: a discrete choice experiment. Prenat Diagn. 2013;33:449–56.
25. Cunningham CE, Chen Y, Deal K, Rimas H, McGrath P, Reid G, et al. The interim service preferences of parents waiting for children’s mental health treatment: a discrete choice conjoint experiment. J Abnorm Child Psych. 2013;41:865–77.
26. Fraenkel L, Suter L, Cunningham CE, Hawker G. Understanding preferences for disease modifying drugs in osteoarthritis. Arthritis Care Res (Hoboken). 2014;66:1186–92.
27. Goossens LM, Utens CM, Smeenk FW, Donkers B, van Schayck OC, Rutten-van Molken MP. Should I stay or should I go home? A latent class analysis of a discrete choice experiment on hospital-at-home. Value Health. 2014;17:588–96.
28. Guo N, Marra CA, FitzGerald JM, Elwood RK, Anis AH, Marra F. Patient preference for latent tuberculosis infection preventive treatment: a discrete choice experiment. Value Health. 2011;14:937–43.
29. Lagarde M. Investigating attribute non-attendance and its consequences in choice experiments with latent class models. Health Econ. 2013;22:554–67.
30. Naik-Panvelkar P, Armour C, Rose JM, Saini B. Patient preferences for community pharmacy asthma services: a discrete choice experiment. Pharmacoeconomics. 2012;30:961–76.
31. Waschbusch DA, Cunningham CE, Pelham WE, Rimas HL, Greiner AR, Gnagy EM, et al. A discrete choice conjoint experiment to evaluate parent preferences for treatment of young, medication naive children with ADHD. J Clin Child Adolescent Psychol. 2011;40:546–61.
32. Whitty JA, Stewart S, Carrington MJ, Calderone A, Marwick T, Horowitz JD, et al. Patient preferences and willingness-to-pay for a home or clinic based program of chronic heart failure management. PLoS One. 2013;8:e58347.
33. Wong YN, Egleston BL, Sachdeva K, Eghan N, Pirollo M, Stump TK, et al. Cancer patients’ trade-offs among efficacy, toxicity, and out-of-pocket cost in the curative and noncurative setting. Med Care. 2013;51:838–45.
34. Woodward AT. A latent class analysis of age differences in choosing service providers to treat mental and substance use disorders. Psychiatr Serv. 2013;64:1087–94.